Telemetry Investments’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Telemetry Investments’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,190	Closed	-$75K	–	133
2017 Q1	$75K	Sell	18,190 -3,310	-15%	-$13.9K	0.03%	113
2016 Q4	$93K	Sell	21,500 -2,167	-9%	-$14K	0.05%	100
2016 Q3	$233K	Sell	23,667 -18,000	-43%	-$128K	0.15%	77
2016 Q2	$236K	Sell	41,667 -4,333	-9%	-$29.4K	0.13%	82
2016 Q1	$351K	Sell	46,000 -4,000	-8%	-$30.8K	0.1%	73
2015 Q4	$666K	Buy	50,000 +10,083	+25%	+$174K	0.23%	69
2015 Q3	$656K	Sell	39,917 -5,916	-13%	-$121K	0.28%	78
2015 Q2	$1.03M	Buy	45,833 +4,166	+10%	+$65.9K	0.46%	49
2015 Q1	$408K	Buy	41,667 +15,750	+61%	+$154K	0.23%	85
2014 Q4	$295K	Buy	+25,917	New	+$281K	0.18%	125

Other funds holding CASC

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Telemetry Investments's CASC Position: Q2 2017 in Review

Telemetry Investments sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 18,190 shares — an estimated $75K sold.

Telemetry Investments first reported a position in CASC in Q4 2014 and held it in 10 quarters. The position peaked at $1.03M in Q2 2015. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

Telemetry Investments reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Telemetry Investments sold 18,190 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $75K.
Telemetry Investments first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 10 quarters.
Telemetry Investments's Cascadian Therapeutics, Inc. position peaked at $1.03M in Q2 2015.
76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Telemetry Investments's 13F filing for Q2 2017, filed 14 Aug 2017.